As synthetic biology continues to grow, advanced benchtop systems are becoming available to make research and product development easier. Now, Inscripta, a digital genome engineering company, has announced the first commercial shipment of its Onyx platform. The platform is the world's first fully automated benchtop instrument for genome-scale engineering. Inscripta also announced its Series E funding of $150 million.